Actavis eyes fast-growing biosimilar market

With a deal on the table to buy up a 51 percent stake in Poland's Bioton, Actavis says it wants to use the move as a springboard into biosimilars. Like a slate of biopharma companies, the Icelandic generic drugmaker sees a big future for companies with the financial wherewithal to develop a new generation of biologics that act in a similar fashion to some of the world's biggest biotech blockbusters. Analysts expect the biosimilar market to hit $10 billion by 2015, but it won't be cheap or easy gaining regulatory approvals. Story